In the News :: Epic Sciences

08.14.2017

Video - Prostate Cancer: Epic Sciences AR-V7 Test

San Diego, OncLive — Insights From: Emmanuel S. Antonarakis, MBBCh, Johns Hopkins Medicine; Andrew J. Armstrong, MD, MSc, Duke Cancer Center; Howard I. Scher, MD, Memorial Sloan Kettering Cancer Center

04.28.2017

Biopharma just can’t get enough of Epic Sciences

San Diego, MedCity News — Epic Sciences has to be one of the coolest kids on the biopharma block, with a new $40 million Series D financing round, a whopping 42 industry partnerships and over 200 clinical trials in the works, all built around its novel liquid biopsy platform. For a team of just 70, the San Diego, California startup is doing pretty well.

04.13.2017

Liquid Biopsy Market Sees Continuing Growth of New Technologies, Methods

New York, GenomeWeb – As liquid biopsy products make further inroads in the clinic and in clinical research, rather than coalescing around a few dominant technologies or platforms, investigators and entrepreneurs are continuing to explore and advance a wide range of methods for examining genomic and other molecular biomarkers non-invasively.

07.07.2016

Genomic Health to Market Epic Sciences' AR-V7 Liquid Biopsy Test

New York, GenomeWeb — Genomic Health and Epic Sciences today announced that they have signed an exclusive agreement under which Genomic Health will commercialize Epic Sciences' AR-V7 liquid biopsy test in the United States.

07.06.2016

Test aids prostate cancer treatment.

New York, Wall Street Journal — Genomic Health Inc. has struck a deal to commercialize a new blood test that can help advanced prostate cancer patients decide whether to try costly new-generation drugs or rely on much cheaper traditional chemotherapy to improve their chances for survival.

06.14.2016

Guest Commentary: Back to cancer’s drawing board.

By Murali Prahalad of Epic Sciences — A curious problem arises for each new precision oncology therapeutic with a companion diagnostic: Many predicted responders exhibit primary resistance.

06.09.2016

Epic Sciences' circulating tumor cell prostate cancer test shows promise in new JAMA study.

Chicago, GenomeWeb — A new study by researchers from Memorial Sloan Kettering Cancer Center has demonstrated the predictive power of an AR-V7 protein expression test using Epic Sciences' non-EPCAM-based circulating tumor cell detection platform, which could help guide treatment decisions for men with metastatic castration-resistant prostate cancer.